ENHO and Hepatic steatosis: Adropin-overexpressing mice or systemic adropin treatment attenuates hepatic steatosis and insulin resistance in DIO (Kumar et al., 2008)Adropin-deficient mice exhibited dyslipidemia and insulin resistance (Gao et al., 2014)Adropin administrations improve glucose homeostasis and protect against DIO (Gao et al., 2019)